The efficacy of recombinant thrombomodulin for post transplant coagulopathy in children

The efficacy of recombinant thrombomodulin for post transplant coagulopathy in children - The efficacy of recombinant thrombomodulin for post transplant children

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005117

Enrollment

Registered

2011-02-21

Start date

2011-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

children with coagulopathy after hematopoietic stem cell transplantation

Interventions

Eligible Patients 1) Children who will be performed hematopoietic stem cell transplantation (HSCT) in this hospital. 2) D-dimer level above 1.0 ug/ml at 5 through 28 days after HSCT. 3) Written inf

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Children who will be performed hematopoietic stem cell transplantation (HSCT) in this hospital. 2) D-dimer level above 1.0 ug/ml at 5 through 28 days after HSCT. 3) Written informed consent will be obtained from patients or parents.

Exclusion criteria

Exclusion criteria: 1) The Patients with bleeding in brain, lung, or intestine. 2) Past history of allergy for recombinant thrombomodulin 3) Patients who refused to participate in the study 4) Other reasons by which physicians decide not to be eligible for the study.

Design outcomes

Primary

Measure	Time frame
To evaluate the safety of recombinant thrombomodulin for children with coagulopathy after hematopoietic stem cell transplantation	—

Secondary

Measure	Time frame
To evaluate the rate to develop microangiopathy after hematopoietic stem cell transplantation	—

Countries

Japan

Contacts

Public ContactReo Tanoshima

Yokohama City University Hospital Department of Pediatrics

tanotch@yokohama-cu.ac.jp045-787-2800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026